StockData
Soligenix, Inc. logo

Soligenix, Inc. (SNGX) stock

SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.28−0.01 (-2.67%)

Close on Nov 17, 2026Market cap $6.11MP/E –Yield –

Soligenix price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Soligenix's price to sales ratio was 41.5× on Apr 30, 2025, against 4.8× a year earlier. Over the last 5 years it ranged from 1.8× to 48.7×, with a median of 14.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Apr 30, 202541.5×+24.5
2024Dec 31, 202417.0×+8.8
2023Dec 29, 20238.2×−14.4
2022Dec 30, 202222.6×−9.8
2021Dec 31, 202132.4×+24.1
2020Dec 31, 20208.3×+3.2
2019Dec 31, 20195.0×+2.3
2018Dec 31, 20182.8×+0.5
2017Dec 29, 20172.3×+1.5
2016Dec 30, 20160.7×−3.2
2015Dec 31, 20154.0×+0.6
2014Dec 31, 20143.3×−9.7
2013Dec 31, 201313.0×+12.1
2012Dec 31, 20120.9×−67.2
2011Dec 30, 201168.1×–

More Soligenix figures

See a number that looks wrong?